Careful therapy of brain lesions

A tumor in the brain means major challenges –  for the patient and for healthcare. In addition, it may be poorly localized making surgery difficult. Passing various nerve centers that control important functions of the body is critical. Supplementary treatment with chemotherapy and radiation is generally needed.

When using laser ablation in neurosurgery, so called laser interstitial thermal therapy (LITT), a region of interest is directly targeted and treated with high precision. Areas in the brain, not accessible for open surgery, can be treated as LITT is typically minially invasive through use of MRI guidance (MRgLITT), and a stereotactic access system.

In collaboration with partners and through clinical programs, CLS is expanding into MRgLITT for treatment of patients with tumors and other lesions in the brain, including epileptogenic foci.

A new dedicated laser therapy system for neurosurgery

A system for MR guided laser ablation in neurosurgery is cleared by the US Food and Drug Administration (FDA) as of September 22, 2022. It is commercialized by our partner ClearPoint Neuro Inc. under the brand name ClearPoint Prism™ Neuro Laser Therapy System, starting in the USA. 

The new system includes CLS’s:

  • Second generation Mobile Laser Unit
  • New Thermoguide Workstation
  • Portfolio of non-cooled Laser Applicators

Evaluating ablation of glioblastoma lesions

A clinical study at Skåne University Hospital, Lund , evaluating safety and feasibility using CLS new system for MRgLITT in minimally invasive ablation of lesions in the brain, such as primary tumors of patients diagnosed with glioblastoma, is now recruiting patients.

About glioblastoma

Glioblastoma is the most aggressive brain tumor and almost incurable. Despite intensive research and drug development the treatment of this disease remains a challenge. Hence, the need for new treatment options to offer affected patients is huge.

Our goal is to develop the field of therapy – by offering tools for precise and cost-efficient treatment.

Contact for more information

Dan J. Mogren

News and insights

17 November, 2023

Customer Experience AVANT Concierge Urology

Learn about our progress within the Mobile Service Provider Model enabling more clinics to treat prostate cancer patients.

Read more
7 November, 2023

Podcast Episode with Insight from the US Market

Listen to a podcast episode with Michael Magnani, President of CLS Americas and Dr Garrett D. Pohlman, urologist at Kearney and the host of the Prostate Health Podcast. They had an engaging discussion around the key features and benefits of using the TRANBERG system for the treatment of low to intermediate localized prostate cancer.

Read more
1 November, 2023

CLS Supports Movember

This month, men all around the world are growing mustaches to raise awareness for men's health issues, such as prostate cancer, testicular cancer, mental health, and suicide prevention. It's more than just a mustache; it's a movement to make a difference in the lives of men everywhere.

Read more

Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!

Please choose your country or region